| Literature DB >> 24070026 |
Hongyou Zhang1, Ling Wu, Chuang Xu, Cheng Xia, Lingwei Sun, Shi Shu.
Abstract
BACKGROUND: Ketosis is an important problem for dairy cows` production performance. However, it is still little known about plasma metabolomics details of dairy ketosis.Entities:
Mesh:
Year: 2013 PMID: 24070026 PMCID: PMC3849279 DOI: 10.1186/1746-6148-9-186
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Main characteristics and blood biochemical parameters in normal control cows (NC), cows with subclinical ketosis (SK), and cows with clinical ketosis (CK)
| Number | 24 | 33 | 24 |
| Days in milk | 12±5 | 14±6 | 16±6 |
| Age | 3±1 | 3±1 | 4±2 |
| Parity | 2±1 | 2±1 | 2±1 |
| MY (kg/d) | 32.1±7.8Aa | 35.2±7.2b | 37.0±6.2Cc |
| BCS | 3.05±0.31a | 3.11±0.35 ab | 3.16±0.37b |
| Glc (mmol/L) | 1.90 ± 0.70A | 2.70±0.63B | 3.37±0.58C |
| BHBA (mmol/L) | 2.49±0.60A | 1.22±0.17B | 0.82±0.12C |
| CHO (mmol/L) | 2.36±0.70 | 2.45±0.68 | 1.98±0.80 |
| AST (U/L) | 113.13±23.74 | 113.29±27.46 | 102.58±28.58 |
| TG (mmol/L) | 0.13±0.40 | 0.16±0.50 | 0.13±0.57 |
Data are shown as mean ± SD, p < 0.05 or 0.01 among CK, SK, and NC groups with different lowcase (a, b, c) or capital letters (A, B, C).
MY milk yield, BCS body condition score, DMI dry matter intake, Glc glucose, BHBA β-hydroxyl acid, CHO cholerol, AST aspartate aminotransferase, TG triglyceride.
Figure 1The representative GC/MS chromatograms of plasma samples from No. 8 of normal control (NC, purple peaks) cows, No. 35 of cows with subclinical ketosis (SK, brown peaks) and No. 68 of cows with clinical ketosis (CK, green peaks). X-axis is retention time (min); Y-axis is intensity of MS (%).
Marker metabolites found in the GC/MS chromatograms of any two groups of CK, SK, and NC
| 1 | LA | 5.68 | 147 | 1.88 | 2.62E-04 | −0.79 | 2.13 | 4.90E-04 | −0.73 | | | | Glycolysis;gluconeogenesis |
| 2 | GLCA | 16.56 | 319 | 1.76 | 6.84E-04 | −0.79 | 2.02 | 1.58E-03 | −0.66 | | | | Pentose and glucuronate interconversions |
| 3 | L-ala | 6.23 | 116 | 2.03 | 8.88E-05 | −0.75 | 1.18 | 4.86E-02 | −0.28 | 2.22 | 1.22E-03 | −0.47 | Alanine and aspartate metabolism |
| 4 | GA | 5.87 | 147 | 1.89 | 1.53E-04 | −0.56 | 2.12 | 5.94E-04 | −0.48 | | | | Fatty acid metabolism |
| 5 | Ribitol | 14.3 | 217 | 1.07 | 3.54E-02 | −0.48 | 1.19 | 4.77E-02 | −0.27 | | | | Glycolysis; Pentose phosphate Pathway |
| 6 | pGlu | 11.83 | 156 | 1.54 | 2.83E-03 | −0.43 | 1.34 | 1.77E-02 | −0.29 | | | | Glutathione metabolism |
| 7 | Gal | 16.03 | 73 | 1.83 | 9.86E-04 | −0.38 | 1.85 | 3.02E-03 | −0.61 | | | | Galactose metabolism |
| 8 | THBA | 12.17 | 292 | 1.46 | 7.32E-04 | −0.38 | 1.43 | 1.77E-02 | −0.24 | | | | Fatty acid metabolism; Butanoate metabolism |
| 9 | Glc | 16.21 | 319 | 1.66 | 2.98E-04 | −0.31 | 1.77 | 2.78E-03 | −0.22 | 2.26 | 2.15E-02 | −0.14 | Glycolysis/gluconeogenesis |
| 10 | Gly | 9.05 | 174 | 1.45 | 1.62E-03 | 0.37 | 2.16 | 4.21E-05 | 0.45 | | | | Glycine, Serine and Threonine Metabolism |
| 11 | L-ile | 8.87 | 158 | 1.67 | 1.72E-04 | 0.41 | 2.2 | 1.97E-05 | 0.44 | | | | Valine, leucine and isoleucine degradation |
| 12 | AABA | 7.19 | 130 | 1.29 | 8.28E-03 | 0.53 | 1.94 | 1.89E-04 | 0.7 | | | | Fatty Acid Metabolism; Glycolysis; Glutamate metabolism; |
| 13 | AMA | 11.19 | 218 | 1.35 | 2.58E-03 | 0.56 | 2.12 | 2.83E-05 | 0.67 | | | | dicarboxylic acid; malonate; biosynthetic formation of glycine |
| 14 | αTP | 26.16 | 502 | 1.79 | 6.08E-03 | 0.57 | 1.11 | 5.02E-02 | 0.41 | | | | Antioxidant |
| 15 | Sitosterol | 28.57 | 357 | 2.25 | 7.58E-07 | 0.70 | 1.37 | 6.92E-03 | 0.41 | 1.69 | 1.71E-02 | 0.29 | Steroid biosynthesis;immunity |
| 16 | HMA | 13.68 | 129 | 1.79 | 2.42E-04 | 0.82 | 1.39 | 6.73E-03 | 0.47 | | | | cholesterol synthesis and fatty acid mobilization |
| 17 | 3HV | 8.05 | 147 | 1.86 | 9.89E-05 | 0.91 | 1.8 | 7.83E-03 | 0.59 | 2.59 | 1.57E-03 | 0.31 | Valine, leucine and isoleucine biosynthesis |
| 18 | PA | 17.26 | 117 | 2.04 | 4.68E-05 | 1.00 | 2.05 | 1.25E-04 | 0.77 | | | | Fatty acid metabolism |
| 19 | HA | 18.17 | 327 | 2.08 | 1.18E-05 | 1.09 | 2.24 | 2.94E-05 | 0.75 | 2.08 | 3.68E-02 | 0.34 | Fatty acid metabolism |
| 20 | SA | 18.71 | 341 | 2.26 | 5.60E-07 | 1.14 | 2.22 | 4.30E-05 | 0.76 | 2.34 | 8.85E-03 | 0.37 | Fatty acid metabolism |
| 21 | BHBA | 7.02 | 147 | 2.58 | 2.83E-10 | 1.33 | 3.06 | 2.43E-10 | 0.81 | 3.32 | 4.49E-05 | 0.53 | Synthesis and degradation of ketone bodies |
| 22 | T-9-OA | 18.82 | 339 | 2.09 | 1.76E-06 | 1.39 | 2.45 | 3.75E-07 | 1.06 | | | | Fatty acid metabolism |
| 23 | MA | 15.36 | 285 | 1.73 | 7.58E-05 | 1.58 | 2.22 | 4.87E-06 | 1.14 | | | | Fatty acid metabolism |
| 24 | C-9-HA | 17.09 | 311 | 1.68 | 9.90E-05 | 1.66 | 2.15 | 6.81E-06 | 1.28 | | | | Fatty acid metabolism |
| 25 | 2PC | 10.23 | 156 | 2.19 | 4.12E-06 | 1.79 | 2.77 | 1.53E-09 | 1.78 | | | | |
| 26 | L-ser | 9.77 | 204 | 1.34 | 1.43E-02 | −0.49 | | | | 2.37 | 3.36E-04 | −0.43 | Glycine, serine, and threonine metabolism |
| 27 | GABA | 11.91 | 84 | 1.73 | 2.91E-04 | −0.71 | | | | 2.27 | 8.44E-04 | −0.48 | Fatty acid metabolism; Glycolysis; Glutamate metabolism; Pyruvate metabolism |
| 28 | Melibiose | 24.37 | 204 | 1.05 | 2.19E-02 | −0.66 | | | | | | | Arginine and proline metabolism |
| 29 | Erythritol | 11.72 | 147 | 1.1 | 1.75E-02 | −0.43 | | | | | | | Galactose metabolism |
| 30 | 3HIV | 7.69 | 75 | 1.05 | 1.24E-02 | −0.26 | | | | | | | Pentose phosphate pathway |
| 31 | 2Me3HB | 7.53 | 117 | 1.34 | 5.91E-03 | 0.36 | | | | | | | Valine, leucine and isoleucine biosynthesis |
| 32 | Xylitol | 14.11 | 307 | 1.2 | 5.67E-03 | 0.42 | | | | | | | Fatty acid metabolism; ketogenesis |
| 33 | 4HYP | 11.88 | 230 | | | | 1.61 | 5.97E-03 | 0.47 | 1.3 | 2.90E-02 | −0.24 | Glycolysis; Pentose phosphate Pathway |
| 34 | L-orn | 15.17 | 142 | | | | 1.16 | 6.00E-02 | −0.68 | | | | Urea Cycle; D-arginine and D-ornithine metabolism |
| 35 | MMA | 8.53 | 319 | | | | 1.33 | 1.83E-02 | −0.39 | | | | dicarboxylic acid;malonate |
| 36 | 2-KG | 12.47 | 73 | | | | 1.17 | 4.48E-02 | −0.26 | | | | TCA Cycle; Glycolysis |
| 37 | L-leu | 8.57 | 158 | | | | 1.28 | 1.84E-02 | 0.19 | | | | Valine, leucine, and isoleucine metabolism |
| 38 | Citrate | 15.24 | 73 | | | | | | | 1.72 | 7.87E-03 | −0.59 | TCA Cycle |
| 39 | DHBA | 10.7 | 73 | | | | | | | 2.28 | 1.75E-02 | −0.29 | Fatty acid metabolism; Butanoate metabolism |
| 40 | L-pro | 8.91 | 142 | 1.53 | 1.43E-02 | −0.22 | Arginine and proline metabolism | ||||||
aSignificant changes in the levels of corresponding metabolites between arbitrary two groups by the ANOVA and t-test (P < 0.05).
2PC 2-piperidinecarboxylic acid, C-9-HA cis-9-hexadecenoic acid, MA myristic acid, T-9-OA Trans-9-octadecenoic acid, BHBA 3-hydroxybutyric acid, SA stearic acid, HA heptadecanoic acid, PA palmitic acid, 3HV 3-hydroxyvaleric acid, HMA 3-hydroxy-3-methylglutaric acid, αTP α-tocopherol, AMA aminomalonic acid, AABA α-aminobutyric acid, L-ile l-isoleucine, Gly glycine, Glc Glucose, THBA 2,3,4-trihydroxybutyric acid, Gal galactose, pGlu pyroglutamic acid, GA glycolic acid, L-ala l-alanine, GLCA glucuronic acid, LA lactic acid, GABA 4-aminobutyric acid, L-ser l-serine, 4HYP 4-hydroxyproline, 3-HIV 3-hydroxyisovaleric acid, 2Me3HB 2-methyl-3-hydroxybutyric acid, L-orn l-ornithine, MMA methylmalonic acid, 2-KG 2-ketoglutaric acid, L-leu l-leucine, Cit citrate, DHB 3,4-dihydroxybutyric acid, L-pro, l-proline.
bRetention time.
cPeaks in total ion chromatograms (TICs) are numbered according to their retention time. The identification of a metabolite is based on National Institute of Standards and Technology (NIST08) mass spectra database according to the match of masses (m/z) between the interested peak’s fragmentation pattern and that from the standard database.
dVariable importance in the projection (VIP) was obtained from OPLS-DA model with value higher than 1.0.
eThe p-value calculated from two-tailed student's t test.
fFold change (FC) was calculated as binary logarithm of average mass response ratio between two groups, where the positive value means that the average mass response of the metabolite in the former is larger than that in the latter and vice versa.
gInformation from KEGG database or NuGOwiki database.
Figure 2Score plot of OPLS-DA among three groups after excluding three outlier samples from Group CK, SK and NC respectively.
Figure 3The OPLS-DA scores plot and ROC plot of plasma obtained from arbitrary two groups. (a, b, c) Score plot of OPLS-DA of using Principal Component 1 (PC1) in Group CK vs. NC, Group SK vs. NC, and Group CK vs. SK respectively; (d, e, f) ROC plot of cis-9-hexadecenoic acid, 2-piperidinecarboxylic acid, and 3-hydroxybutyric acid in the diagnosis in Group CK vs. NC, Group SK vs. NC, and Group CK vs. SK respectively.
Figure 4Intensity of metabolites from CK compared to NC (blue column), SK compared to NC (red column), and CK compared to SK (yellow column). (a) Expression intensity of 25 identical metabolites from CK vs. NC and SK vs. NC, including 7 metabolites from CK vs. SK. 2PC, 2-piperidinecarboxylic acid; C-9-HA, cis-9-hexadecenoic acid; MA, myristic acid; T-9-OA, Trans-9-octadecenoic acid; BHBA, 3-hydroxybutyric acid; SA, stearic acid; HA, heptadecanoic acid; PA, palmitic acid; 3HV, 3-hydroxyvaleric acid; HMA, 3-hydroxy-3-methylglutaric acid; VE, vitamin E (α-tocopherol); AMA, aminomalonic acid; AABA, α-aminobutyric acid; L-ile, l-isoleucine; Gly, glycine; Glc, Glucose; THBA, 2,3,4-trihydroxybutyric acid; Gal, galactose; pGlu, pyroglutamic acid; GA, glycolic acid; L-ala, l-alanine; GLCA, glucuronic acid; LA, lactic acid. (b) Expression intensity of 15 different metabolites from three groups. GABA, 4-aminobutyric acid; L-ser, l-serine; 4HYP, 4-hydroxyproline; 3-HIV, 3-hydroxyisovaleric acid; 2Me3HB, 2-methyl-3-hydroxybutyric acid; L-orn, l-ornithine; MMA, methylmalonic acid; 2-KG, 2-ketoglutaric acid; L-leu, l-leucine; Cit, citrate; DHB, 3,4-dihydroxybutyric acid; L-pro, l-proline.
The potential diagnostic biomarkers of any two groups of CK, SK, and NC
| 1 | GA | 0.25 | 0.122 | 0.38 | 0.176 | | |
| 2 | L-ala | 0.06 | 0.149 | | | 0.30 | 0.216 |
| 3 | L-ser | | | | | 0.36 | 0.240 |
| 4 | GLCA | 0.19 | 0.153 | 0.05 | 0.19 | | |
| 5 | Erythritol | 0.28 | 0.161 | | | | |
| 6 | Ribitol | 0.26 | 0.171 | | | | |
| 7 | Glc | 0.24 | 0.176 | 1.07 | 0.259 | | |
| 8 | LA | 0.07 | 0.178 | 0.18 | 0.199 | | |
| 9 | Gal | 0.34 | 0.184 | 0.42 | 0.22 | | |
| 10 | GABA | 0.15 | 0.221 | | | 0.26 | 0.261 |
| 11 | DHB | | | | | 0.36 | 0.257 |
| 12 | THB | 0.38 | 0.231 | | | | |
| 13 | pGlu | 0.47 | 0.269 | | | | |
| 14 | MMA | | | 1.01 | 0.283 | | |
| 15 | Melibiose | 1.05 | 0.277 | | | | |
| 16 | Citrate | | | | | 0.42 | 0.281 |
| 17 | 3HV | | | 2.32 | 0.79 | | |
| 18 | AABA | | | 11.80 | 0.79 | | |
| 19 | L-leu | 1.89 | 0.638 | | | | |
| 20 | Xylitol | 3.16 | 0.752 | | | | |
| 21 | Gly | 2.33 | 0.76 | 7.90 | 0.837 | | |
| 22 | 2Me3HB | 3.60 | 0.764 | | | | |
| 23 | AMA | 2.57 | 0.773 | 3.09 | 0.822 | | |
| 24 | AABA | 1.05 | 0.773 | | | | |
| 25 | αTP | 2.37 | 0.783 | | | | |
| 26 | L-ile | 3.16 | 0.814 | 3.32 | 0.827 | | |
| 27 | HMG | 4.07 | 0.848 | | | | |
| 28 | Sitosterol | 3.00 | 0.88 | | | 1.91 | 0.741 |
| 29 | PA | 6.35 | 0.897 | 5.29 | 0.838 | | |
| 30 | C-9-HA | 3.81 | 0.909 | 2.75 | 0.842 | | |
| 31 | Hep | 7.02 | 0.911 | 5.15 | 0.866 | | |
| 32 | MA | 6.01 | 0.913 | 3.21 | 0.845 | | |
| 33 | SA | 6.35 | 0.913 | 3.44 | 0.842 | | |
| 34 | 2PC | 4.97 | 0.918 | 7.78 | 0.923 | | |
| 35 | T-9-OA | 4.21 | 0.924 | 3.58 | 0.868 | | |
| 36 | 3HV | 9.09 | 0.95 | | | 2.38 | 0.764 |
| 37 | BHBA | 10.22 | 0.977 | 8.13 | 0.965 | 5.11 | 0.953 |
aAbbreviations of compounds’ name are same as Table 2.
b+LR, positive likelihood ratio.
cAUC, area under the curve. If AUC value is more than 7.00 or less than 0.30, compound is considered to be a potential diagnostic biomarker of disease.